[go: up one dir, main page]

TW200518746A - Novel inhibitors of hepatitis C virus NS3/NS4A serine protease - Google Patents

Novel inhibitors of hepatitis C virus NS3/NS4A serine protease

Info

Publication number
TW200518746A
TW200518746A TW093138050A TW93138050A TW200518746A TW 200518746 A TW200518746 A TW 200518746A TW 093138050 A TW093138050 A TW 093138050A TW 93138050 A TW93138050 A TW 93138050A TW 200518746 A TW200518746 A TW 200518746A
Authority
TW
Taiwan
Prior art keywords
hepatitis
virus
serine protease
novel inhibitors
ns4a serine
Prior art date
Application number
TW093138050A
Other languages
English (en)
Inventor
Francisco Velazquez
Srikanth Venkatraman
Ashok Arasappan
F George Njoroge
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34699904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200518746(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of TW200518746A publication Critical patent/TW200518746A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093138050A 2003-12-11 2004-12-09 Novel inhibitors of hepatitis C virus NS3/NS4A serine protease TW200518746A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52884503P 2003-12-11 2003-12-11

Publications (1)

Publication Number Publication Date
TW200518746A true TW200518746A (en) 2005-06-16

Family

ID=34699904

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093138050A TW200518746A (en) 2003-12-11 2004-12-09 Novel inhibitors of hepatitis C virus NS3/NS4A serine protease

Country Status (18)

Country Link
US (1) US7485625B2 (zh)
EP (1) EP1742913A1 (zh)
JP (1) JP2007513971A (zh)
KR (1) KR20060118532A (zh)
CN (1) CN100509784C (zh)
AR (1) AR046758A1 (zh)
AU (1) AU2004298498B2 (zh)
BR (1) BRPI0416902A (zh)
CA (1) CA2549167A1 (zh)
CO (1) CO5700736A2 (zh)
EC (1) ECSP066626A (zh)
IL (1) IL176237A0 (zh)
NO (1) NO20063205L (zh)
PE (1) PE20050940A1 (zh)
RU (1) RU2006124594A (zh)
TW (1) TW200518746A (zh)
WO (1) WO2005058821A1 (zh)
ZA (1) ZA200604638B (zh)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
CN101212970B (zh) * 2005-06-02 2010-07-21 先灵公司 Hcv蛋白酶抑制剂与表面活性剂的组合物
US20100017895A1 (en) * 2005-07-18 2010-01-21 Amy Weiner Small animal model for hcv replication
SG166791A1 (en) * 2005-07-25 2010-12-29 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
KR20080056295A (ko) * 2005-10-11 2008-06-20 인터뮨, 인크. Ｃ형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20140098867A (ko) 2005-11-11 2014-08-08 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 변이체
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US8183413B2 (en) 2006-01-20 2012-05-22 Kaneka Corporation Process for production of β-amino-α-hydroxy carboxamide derivative
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007120595A2 (en) * 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
WO2007137080A2 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
US7834190B2 (en) * 2006-05-26 2010-11-16 Kaneka Corporation Process for production of optically active-3-amino-2-hydroxypropionic cyclopropylamide derivatives and salts thereof
US9526769B2 (en) * 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
TWI454264B (zh) * 2006-06-26 2014-10-01 Enanta Pharm Inc 喹啉基巨環ｃ型肝炎病毒絲胺酸蛋白酶抑制劑
DE102006059317A1 (de) 2006-07-04 2008-01-10 Evonik Degussa Gmbh Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7662779B2 (en) * 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
EP2054388A4 (en) 2006-08-17 2009-10-28 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
WO2008027397A2 (en) * 2006-08-28 2008-03-06 Vertex Pharmaceuticals Incorporated Method for identifying protease inhibitors
US20100216161A1 (en) 2009-02-26 2010-08-26 Vertex Pharmaceuticals Incorporated Method for identifying protease inhibitors
DE102006042147A1 (de) * 2006-09-06 2008-03-27 Dynamit Nobel Gmbh Explosivstoff- Und Systemtechnik Hydrochloride von 3-Amino-2-hydroxycarbonsäureamiden
US8003604B2 (en) * 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010512317A (ja) 2006-12-07 2010-04-22 シェーリング コーポレイション ｐＨ感受性マトリクス処方物
BRPI0807483A2 (pt) 2007-02-09 2014-05-13 Irm Llc Compostos e composições como inibidores de protease de ativação de canal
MX2009011867A (es) * 2007-05-03 2010-03-22 Array Biopharma Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
AR068756A1 (es) 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US8268777B2 (en) * 2007-12-05 2012-09-18 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
BRPI0821342A2 (pt) 2007-12-19 2019-09-24 Boehringer Ingelheim Int inibidores da polimerase viral
JP2011051896A (ja) * 2007-12-21 2011-03-17 Kaneka Corp Ｎ−シクロプロピル−３−アミノ−２−ヒドロキシヘキサン酸アミド塩酸塩の製造方法
BRPI0911260A2 (pt) 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
EP2300491B1 (en) * 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US20100272674A1 (en) * 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
SG179566A1 (en) * 2009-09-15 2012-05-30 Taigen Biotechnology Co Ltd Hcv protease inhibitors
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US20120329704A1 (en) * 2010-02-25 2012-12-27 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patieentenzorg Process for the preparation of substituted prolyl peptides and similar peptidomimetics
PE20130062A1 (es) 2010-03-09 2013-02-28 Merck Sharp & Dohme Compuestos de sililo triciclicos fusionados para el tratamiento de enfermedades virales
US20140377223A1 (en) 2010-07-26 2014-12-25 Joseph A. Kozlowski Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US9254292B2 (en) 2010-09-29 2016-02-09 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
PE20140039A1 (es) 2010-12-30 2014-03-01 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
AR091192A1 (es) 2012-05-30 2015-01-21 Chemo Iberica Sa Procedimiento multicomponente para la preparacion de compuestos biciclicos
EP2861557A1 (en) 2012-06-13 2015-04-22 Janssen Pharmaceutica, N.V. A method for the preparation of 3-amino-n-cyclopropyl-2-hydroxyl-hexanamide
CN102875648B (zh) * 2012-09-26 2014-02-19 深圳翰宇药业股份有限公司 一种制备特拉匹韦的方法
CN102875649B (zh) * 2012-09-26 2014-04-16 深圳翰宇药业股份有限公司 一种制备特拉匹韦及其中间体的方法及所述中间体
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
CN104610272B (zh) * 2013-11-05 2017-03-29 上海唐润医药科技有限公司 环状黄酮或异黄酮类化合物及其用途
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3216325A (en) * 1962-04-16 1965-11-09 Dole Valve Co Pneumatic control system
DE60111509T2 (de) 2000-04-03 2006-05-11 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von Serin-Proteasen, insbesondere der Hepatitis-C-Virus NS23-Protease
AU2001276988B2 (en) 2000-07-21 2007-01-25 Dendreon Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
HUP0303436A2 (hu) 2000-12-12 2004-01-28 Schering Corp. Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE60329367D1 (de) * 2002-01-23 2009-11-05 Schering Corp Verwendung bei der bekämpfung von hepatitis c virusinfektion

Also Published As

Publication number Publication date
KR20060118532A (ko) 2006-11-23
CN100509784C (zh) 2009-07-08
EP1742913A1 (en) 2007-01-17
CA2549167A1 (en) 2005-06-30
IL176237A0 (en) 2006-10-05
AU2004298498B2 (en) 2008-09-11
CO5700736A2 (es) 2006-11-30
CN1890215A (zh) 2007-01-03
AR046758A1 (es) 2005-12-21
NO20063205L (no) 2006-09-08
PE20050940A1 (es) 2005-11-08
BRPI0416902A (pt) 2007-01-16
US20050153900A1 (en) 2005-07-14
ECSP066626A (es) 2006-10-25
RU2006124594A (ru) 2008-01-27
ZA200604638B (en) 2007-04-25
JP2007513971A (ja) 2007-05-31
WO2005058821A1 (en) 2005-06-30
AU2004298498A1 (en) 2005-06-30
US7485625B2 (en) 2009-02-03

Similar Documents

Publication Publication Date Title
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
TW200508220A (en) Hepatitis C inhibitor compounds
IL152022A0 (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
MY148123A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200602037A (en) Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
NO20044897L (no) Hepatitt C virus inhibitorer
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
EP1506000A4 (en) HETEROCYCLIC SULPHONAMIDE HEPATITIS C VIRUS HEMMER
MY145081A (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
SG164376A1 (en) Hcv ns3 protease inhibitors